Published 26. 07. 2022
The article by the author team from the Department of the Molecular Biology of Cancer, entitled "5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future", published in the prestigious journal Pharmacology and Therapeutics (IF=13.4), is the second most cited article in this highly ranked journal. During the last two years since the publication of this paper, it has been cited 168 times.
The article was co-authored by scientists from the IEM CAS (S. Vodenková, K. Červená, P. Vodička, V. Vymetálková) in collaboration with doctors from the Thomayer University Hospital in Prague, doc. MUDr. Tomáš Büchler and MUDr. Veronika Veškrnová, Ph.D. At the end of last year, these authors were awarded the Prize for Outstanding Research, Experimental Development and Innovation.
The publication presents all the molecular mechanisms of chemoresistance in colorectal cancer patients known so far. It also focuses on the different prodrugs of 5-fluorouracil, developed to increase the amount of circulating 5-FU and reduce its toxicity. Among other things, the article suggests future directions for personalized therapy of colorectal cancer according to the latest published results.